Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 37,800 shares, a decline of 49.5% from the March 31st total of 74,800 shares. Based on an average daily volume of 770,200 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ACHL shares. Chardan Capital lowered their price target on Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, April 5th. Piper Sandler restated a “neutral” rating and set a $2.00 target price (down from $8.00) on shares of Achilles Therapeutics in a report on Friday, April 5th.

Institutional Investors Weigh In On Achilles Therapeutics

A hedge fund recently bought a new stake in Achilles Therapeutics stock. Vestal Point Capital LP acquired a new stake in Achilles Therapeutics plc (NASDAQ:ACHL) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 108,083 shares of the company’s stock, valued at approximately $96,000. Vestal Point Capital LP owned 0.27% of Achilles Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 56.38% of the company’s stock.

Achilles Therapeutics Stock Down 1.2 %

Shares of ACHL opened at $0.77 on Friday. The company has a market cap of $30.88 million, a P/E ratio of -0.45 and a beta of 1.09. Achilles Therapeutics has a fifty-two week low of $0.74 and a fifty-two week high of $1.76. The firm’s 50 day moving average price is $1.11 and its 200 day moving average price is $0.96.

Achilles Therapeutics (NASDAQ:ACHL) last posted its quarterly earnings results on Thursday, April 4th. The company reported ($0.46) EPS for the quarter. Research analysts forecast that Achilles Therapeutics will post -1.34 earnings per share for the current year.

Achilles Therapeutics Company Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.